Physician profile
John M Ord
NPI 1356337109
$2,237.13
in general payments reported to CMS, 2019-2025
26 companies · $40.48 in 2025
The $40.48 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $639 · 2020: $106 · 2021: $175 · 2022: $250 · 2023: $270 · 2024: $758 · 2025: $40.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,068.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,067.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $274.00 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Pfizer INC. | $260.09 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $210.35 | 2019-2024 | |
| Boston Scientific Corporation | $198.83 | 2020-2023 | Watchman Access System, Varithena Administration Pack |
| Heartflow, INC. | $174.31 | 2024 | |
| Janssen Pharmaceuticals, INC | $160.21 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $159.32 | 2019 | |
| Philips North America LLC | $122.74 | 2019-2022 | |
| Amgen INC. | $108.40 | 2019-2022 | |
| Medtronic, INC. | $101.86 | 2024 | Symplicity G3 |
| Kiniksa Pharmaceuticals, LTD. | $78.42 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $56.07 | 2019-2022 | |
| Impulse Dynamics (USA) INC. | $38.17 | 2022-2023 | Optimizer |
| Cardiva Medical, INC. | $37.53 | 2021-2022 | |
| Astellas Pharma US INC | $33.54 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Preventice Services, LLC | $31.48 | 2019 | |
| Siemens Medical Solutions USA, INC. | $24.92 | 2021 | |
| Gilead Sciences, INC. | $24.06 | 2019 | |
| Merck Sharp & Dohme LLC | $23.30 | 2022 | |
| Genzyme Corporation | $22.62 | 2023 | |
| Alnylam Pharmaceuticals INC. | $19.58 | 2024 | Onpattro |
| Biotronik INC. | $19.09 | 2019 | |
| Bardy Diagnostics, INC. | $17.37 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $16.19 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $13.72 | 2019 | |
| Amarin Pharma, INC. | $10.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ord listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.